Archiv der Kategorie ‘Vertex Pharmaceuticals‘

Vertex Pharm (VRTX) Downgrade from Buy to Neutral – Analyst rating from Summer Street Research

Wednesday, den 30. October 2013

Vertex Pharmaceuticals to Cut Workforce 15%

Tuesday, den 29. October 2013

Commit To Purchase Vertex Pharmaceuticals At $55, Earn 13.3%

Saturday, den 15. June 2013

Vertex Pharmaceuticals Shares Surge on Cystic Fibrosis Data

Friday, den 19. April 2013

Vertex Pharm (VRTX) Upgrade from Hold to Buy – Analyst rating from Canaccord Genuity

Friday, den 19. April 2013

Vertex Pharm (VRTX) Initial Recommendation Buy Analyst rating from Chardan Capital Markets

Wednesday, den 10. April 2013

Vertex Pharm (VRTX) Initial Recommendation Outperform Analyst rating from Robert W. Baird

Thursday, den 7. February 2013

Vertex Pharm (VRTX) Downgrade from Buy to Hold – Analyst rating from Argus

Wednesday, den 28. November 2012

Vertex Pharmaceuticals neutral – New Analyst Rating from Credit Suisse Group

Tuesday, den 13. November 2012

Vertex Pharmaceuticals buy – New Analyst Rating from UBS AG

Friday, den 2. November 2012

Vertex Pharmaceuticals kaufen – New Analyst Rating from Fuchsbriefe

Friday, den 27. July 2012

Vertex Pharmaceuticals overweight – New Analyst Rating from Barclays Capital

Tuesday, den 12. June 2012

Vertex Pharmaceuticals overweight – New Analyst Rating from Barclays Capital

Tuesday, den 29. May 2012

Vertex Pharmaceuticals overweight – New Analyst Rating from Barclays Capital

Monday, den 28. May 2012

Vertex Pharmaceuticals buy – New Analyst Rating from Needham & Company, LLC

Wednesday, den 9. May 2012

Vertex Pharmaceuticals overweight – New Analyst Rating from Barclays Capital

Wednesday, den 9. May 2012

Vertex Pharm (VRTX) Upgrade from Hold to Buy – Analyst rating from Needham

Tuesday, den 8. May 2012

Vertex Pharmaceuticals overweight – New Analyst Rating from Barclays Capital

Thursday, den 12. April 2012

Vertex Pharmaceuticals neutral – New Analyst Rating from UBS AG

Thursday, den 29. March 2012

Vertex Pharmaceuticals neutral – New Analyst Rating from UBS AG

Wednesday, den 28. March 2012

Vertex Pharmaceuticals neutral – New Analyst Rating from Goldman Sachs Group Inc.

Monday, den 6. February 2012

Vertex Pharmaceuticals overweight – New Analyst Rating from Barclays Capital

Thursday, den 2. February 2012

Vertex Pharmaceuticals outperform – New Analyst Rating from Credit Suisse Group

Friday, den 16. December 2011

Vertex Pharmaceuticals buy – New Analyst Rating from Citigroup Corp.

Monday, den 5. December 2011

Vertex Pharmaceuticals buy – New Analyst Rating from Citigroup Corp.

Wednesday, den 23. November 2011

Vertex Pharmaceuticals buy – New Analyst Rating from Citigroup Corp.

Tuesday, den 22. November 2011

Vertex Pharmaceuticals neutral – New Analyst Rating from Robert W. Baird & Co. Incorporated

Wednesday, den 9. November 2011

Vertex Pharm (VRTX) Downgrade from Outperform to Neutral – Analyst rating from Robert W. Baird

Tuesday, den 8. November 2011

Vertex Pharmaceuticals neutral – New Analyst Rating from Robert W. Baird & Co. Incorporated

Tuesday, den 8. November 2011

Vertex Pharm ( VRTX ) Downgrade from Outperform to Neutral($33) – Analyst rating from Robert W. Baird

Tuesday, den 8. November 2011

Vertex Pharmaceuticals sector perform – New Analyst Rating from RBC Capital Markets

Tuesday, den 8. November 2011

Vertex Pharm (VRTX) Downgrade from Outperform to Sector Perform – Analyst rating from RBC Capital Mkts

Monday, den 7. November 2011

Vertex Pharmaceuticals sector perform – New Analyst Rating from RBC Capital Markets

Monday, den 7. November 2011

Vertex Pharm ( VRTX ) Downgrade from Outperform to Sector Perform($48) – Analyst rating from RBC Capital Mkts

Monday, den 7. November 2011

Vertex Pharmaceuticals outperform – New Analyst Rating from RBC Capital Markets

Friday, den 14. October 2011

Vertex Pharmaceuticals outperform – New Analyst Rating from RBC Capital Markets

Thursday, den 13. October 2011

Vertex Pharmaceuticals buy – New Analyst Rating from Citigroup Corp.

Wednesday, den 5. October 2011

Vertex Pharm ( VRTX ) Upgrade from Mkt Perform to Mkt Outperform($53) – Analyst rating from JMP Securities

Tuesday, den 4. October 2011

Vertex Pharm (VRTX) Upgrade from Mkt Perform to Mkt Outperform – Analyst rating from JMP Securities

Tuesday, den 4. October 2011

Vertex Pharmaceuticals buy – New Analyst Rating from Citigroup Corp.

Wednesday, den 7. September 2011

Vertex Pharmaceuticals buy – New Analyst Rating from Citigroup Corp.

Tuesday, den 30. August 2011

Vertex Pharmaceuticals outperform – New Analyst Rating from William Blair

Thursday, den 18. August 2011

Vertex Pharm ( VRTX ) Initial Recommendation Neutral – Analyst rating from UBS

Thursday, den 7. July 2011

Vertex Pharm (VRTX) Initial Recommendation – Neutral – Analyst rating from UBS

Thursday, den 7. July 2011

Vertex Pharm (VRTX) Downgrade from Buy to Hold – Analyst rating from Brean Murray

Wednesday, den 4. May 2011